everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...7071727374757677787980...132133»
  • ||||||||||  Afinitor (everolimus) / Novartis
    Clinical, Journal:  Breast cancer organoids from a patient with giant papillary carcinoma as a high-fidelity model. (Pubmed Central) -  Mar 25, 2020   
    The drug sensitivities of our breast papillary carcinoma organoids were investigated as follows, Fulvestrant (IC 0.275 μmol), Palbociclib (IC 2.21 μmol), BKM120 (IC 3.81 μmol), Everolimus (IC 4.45 μmol), Tamoxifen (IC 19.13 μmol). These results showed that an effective organoid platform for 3-D in vitro culture of breast cancer organoids from patients with breast papillary carcinoma could be used to identify possible treatments, and might be commonly applied to explore clinicopathological characteristics of breast papillary carcinoma.
  • ||||||||||  Afinitor (everolimus) / Novartis
    Clinical, Journal:  A Child With Lymphangioma due to Somatic Mutation in PIK3CA Successfully Treated With Everolimus. (Pubmed Central) -  Mar 24, 2020   
    These results showed that an effective organoid platform for 3-D in vitro culture of breast cancer organoids from patients with breast papillary carcinoma could be used to identify possible treatments, and might be commonly applied to explore clinicopathological characteristics of breast papillary carcinoma. No abstract available
  • ||||||||||  FDA event, Review, Journal:  Properties of FDA-approved small molecule protein kinase inhibitors. (Pubmed Central) -  Mar 24, 2020   
    Nearly half of the antagonists (23) have a lipophilic efficiency with values of less than five while the recommended optima range from 5-10. One of the vexing problems is the near universal development of resistance that is associated with the use of small molecule protein kinase inhibitors for the treatment of cancer.
  • ||||||||||  Afinitor (everolimus) / Novartis
    Biomarker, Journal:  Therapeutic drug monitoring of Everolimus in oncology: evidences and perspectives. (Pubmed Central) -  Mar 24, 2020   
    The last consensus conference about the TDM of everolimus states that for the use of everolimus in oncology "Further studies are required to determine the clinical utility of TDM for everolimus in oncology settings". In this review, the authors will discuss the current evidences and perspectives, based on observational studies available, in favor of the TDM of everolimus in oncology focusing on (i) the management of everolimus in routine practice, (ii) the prerequisites for TDM of everolimus in oncology, (iii) the pharmacodynamics (including a description of the biomarker of resistance and mutations in m-TOR) and (iv) a general outlook.
  • ||||||||||  itacitinib (INCB039110) / Incyte
    Enrollment open, Combination therapy:  Itacitinib + Everolimus in Hodgkin Lymphoma (clinicaltrials.gov) -  Mar 24, 2020   
    P1/2,  N=28, Recruiting, 
    Our findings contribute to our knowledge of the interplay between autophagy and cell cycle regulation mediated by mTORC1 signaling and Cyclin D1 regulation. Active, not recruiting --> Recruiting
  • ||||||||||  itacitinib (INCB039110) / Incyte
    Enrollment closed, Combination therapy:  Itacitinib + Everolimus in Hodgkin Lymphoma (clinicaltrials.gov) -  Mar 23, 2020   
    P1/2,  N=28, Active, not recruiting, 
    Trial completion date: Dec 2018 --> Dec 2020 Recruiting --> Active, not recruiting
  • ||||||||||  simvastatin / Generic mfg., Afinitor (everolimus) / Novartis
    Journal:  Time-dependently slow-released multiple-drug eluting external sheath for efficient long-term inhibition of saphenous vein graft failure. (Pubmed Central) -  Mar 23, 2020   
    Under the joint action of mechanical restriction of the sheath and the synergistic effect of loaded fasudil dihydrochloride and everolimus, the endothelium damage and the proliferation/migration of smooth muscle cells, which were thought to be the early cause of graft failure, could be efficiently alleviated. Moreover, the long-term patency could be expected due to the inhibition of atherosclerosis by the sustained released simvastatin.
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Local treatment for focal progression in metastatic neuroendocrine tumors. (Pubmed Central) -  Mar 20, 2020   
    Median time to any additional intervention was 19 months (95% CI, 8.7 - 25.3 months). Control of local sites of progression enabled the majority of patients to remain on their existing systemic treatment and avoid potential toxicities associated with salvage systemic therapy.
  • ||||||||||  Afinitor (everolimus) / Novartis
    Journal:  On-Chip Synthesis of Hyaluronic Acid-Based Nanoparticles for Selective Inhibition of CD44+ Human Mesenchymal Stem Cell Proliferation. (Pubmed Central) -  Mar 19, 2020   
    HA/CS NPs were successfully loaded with a challenging water-insoluble molecule, Everolimus (EVE), an FDA- and EMA-approved anticancer drug able to lead to cell cycle arrest, reduced angiogenesis and promotion of apoptosis...HA/CS NPs selectiveness towards CD44 was highlighted by blocking CD44 receptor by anti-CD44 primary antibody and by comparison to CS-based NPs cellular uptake. Eventually, high effectiveness in inhibiting cell proliferation was demonstrated on-chip synthetized EVE loaded HA/CS NPs by tracking in vitro DNA synthesis.
  • ||||||||||  Afinitor (everolimus) / Novartis, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Retrospective data, Review, Journal:  Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis. (Pubmed Central) -  Mar 18, 2020   
    If activity of mTORi monotherapy is related to mutFBXW7-dependent increased mTOR signaling, approximately 1 in 8 advanced cSCC patients could similarly benefit. Lenvatinib with everolimus, cabozantinib and nivolumab are effective in prolonging the survival for people with amRCC subsequent to VEGF-targeted treatment, but there is considerable uncertainty about how they compare to each other and how much better they are than axitinib and sorafenib.
  • ||||||||||  letrozole / Generic mfg., everolimus / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) -  Mar 18, 2020   
    P2,  N=40, Active, not recruiting, 
    Lenvatinib with everolimus, cabozantinib and nivolumab are effective in prolonging the survival for people with amRCC subsequent to VEGF-targeted treatment, but there is considerable uncertainty about how they compare to each other and how much better they are than axitinib and sorafenib. Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> May 2020 | Trial primary completion date: Dec 2019 --> Mar 2020
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date, Trial primary completion date, Metastases:  Desiree: Dose EScalation Induction of EvERolimus (clinicaltrials.gov) -  Mar 17, 2020   
    P2,  N=156, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> May 2020 | Trial primary completion date: Dec 2019 --> Mar 2020 Trial completion date: Mar 2018 --> Mar 2021 | Trial primary completion date: Mar 2018 --> Dec 2020
  • ||||||||||  Afinitor (everolimus) / Novartis
    False Positive 68Ga-DOTATATE PET/CT in a Patient with Small Bowel Carcinoid Tumor (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area A) -  Mar 15, 2020 - Abstract #ATS2020ATS_8891;    
    Octreotide was discontinued and everolimus was initiated for presumed disease progression however, after two weeks, everolimus was discontinued due to associated drug fever...He was treated with itraconazole and at six month follow-up, symptoms had significantly improved and adenopathy had decreased.NETs are a heterogeneous group of tumors that express variable levels of cell surface somatostatin receptors...In our patient, Cryptococcus infection was not suspected however, the low avidity that was substantially lower than the primary tumor was an indication that this was an alternative process rather than metastatic disease. Clinicians need to keep these pitfalls in mind and consider alternative processes which may lead to change in management.
  • ||||||||||  Afinitor (everolimus) / Novartis, sirolimus / Generic mfg.
    Sporadic Lymphangioleiomyomatosis: A Rare Cause of Spontaneous Pneumothorax in Women (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area H) -  Mar 15, 2020 - Abstract #ATS2020ATS_7966;    
    Our patient presented with classic characteristics of a rare disorder. With no evidence of Tuberous Sclerosis, she was diagnosed with Sporadic Lymphangioleiomyomatosis.
  • ||||||||||  doxycycline / Generic mfg., Afinitor (everolimus) / Novartis
    A Rare Case of Everolimus Induced Organizing Pneumonia (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area H) -  Mar 15, 2020 - Abstract #ATS2020ATS_6613;    
    She was admitted 7 days prior for community-acquired pneumonia and finished a 7-day course of Cefdinir and doxycycline without improvement...She received fluid resuscitation along with IV Vancomycin and Cefepime...She was started on oral prednisone with clinical improvement...Everolimus is used to treat angiomyolipomas in patients with tuberous sclerosis complex. Rarely, it can cause organizing pneumonia which can be treated with discontinuation of the medication and oral corticosteroids.
  • ||||||||||  tacrolimus / Generic mfg., Afinitor (everolimus) / Novartis
    Impulse Oscillometry for the Diagnosis of Bronchiolitis Obliterans Syndrome After Lung Transplantation (PENNSYLVANIA CONVENTION CENTER, Room 122 A-B (100 Level)) -  Mar 15, 2020 - Abstract #ATS2020ATS_3228;    
    Significant variations in the IOS parameters did not occur earlier than the decrease in FEV1.ConclusionsSignificant variations in IOS parameters are associated with BOS occurrence after LT. However, IOS did not allow an earlier detection of BOS than standard pulmonary functional tests.
  • ||||||||||  temozolomide / Generic mfg., everolimus / Generic mfg.
    Trial completion date, Trial primary completion date:  Everolimus With and Without Temozolomide in Adult Low Grade Glioma (clinicaltrials.gov) -  Mar 11, 2020   
    P2,  N=27, Active, not recruiting, 
    Electrochemical conversion of target compounds has appeared as a new pseudo-in vitro instrumental technology for the prediction of potential metabolites, since the oxidation products have also been identified in serum samples. Trial completion date: Jan 2020 --> Sep 2021 | Trial primary completion date: Jan 2020 --> Jul 2021
  • ||||||||||  Afinitor (everolimus) / Novartis
    Journal:  Association of prolactin receptor (PRLR) variants with prolactinomas. (Pubmed Central) -  Mar 10, 2020   
    Treatment of cells with an Akt1/2 inhibitor or everolimus, which acts on the Akt pathway, reduced Asn492Ile signaling and proliferation to wild-type levels. Thus, our results identify an association between a gain-of-function PRLR variant and prolactinomas, and reveal a new aetiology and potential therapeutic approach for these neoplasms.
  • ||||||||||  Farydak (panobinostat) / Secura Bio
    Trial completion, Trial completion date, Combination therapy, Epigenetic controller:  Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma (clinicaltrials.gov) -  Mar 10, 2020   
    P1/2,  N=124, Completed, 
    CONCLUSIONS Cyclosporine, Everolimus, and Belatacept suppressed the alloresponse of primary human hepatocytes in an MLHC without significant cytotoxicity or functional cell impairment. Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Jul 2019
  • ||||||||||  Afinitor (everolimus) / Novartis
    Impact of Pharmacist Management of Patients Receiving Oral Chemotherapy in an Outpatient Breast Cancer Clinic () -  Mar 9, 2020 - Abstract #HOPA2020HOPA_287;    
    Expected conclusion will address changes in clinic flow and practice, impact on patient outcomes, and future possibilities for implementation of this protocol. Pharmacist appointments are expected to increase access to care for the breast cancer patients, who are at a greater risk of adherence issues and developing treatment toxicities, ultimately requiring closer monitoring and follow-up.